The Walt Disney Company's board of directors is set to meet next week, with sources indicating a final vote on the long-awaited CEO succession plan is imminent. The decision comes as Bob Iger's contract nears its end and follows a turbulent period of leadership transition at the media giant.
Deutsche Bank has upgraded NNN REIT to 'Buy' with a $47 price target, highlighting its defensive portfolio and sustainable dividends as relative strengths in a challenging real estate investment trust environment expected to persist through 2026.
Private equity giant Thoma Bravo is exploring a sale of Imprivata, a key player in healthcare digital identity software, in a deal that could value the company at up to $7 billion, sources tell Reuters.
New CMS reimbursement rates are pressuring Medicare Advantage profits, sending shares of Humana and CVS Health lower. We analyze whether the sell-off presents a buying opportunity for dividend investors or signals deeper structural challenges.
With low adoption rates for brokerage 'trusted contacts,' regulators are considering a simple name change to 'emergency contact' to reduce confusion, ease client concerns, and strengthen protections against financial exploitation.
While stocks priced between $10 and $50 often signal companies past their initial hurdles, some still grapple with unproven models and market volatility. We examine three such stocks where the risk may outweigh the potential reward.
While consumer staples are traditionally seen as safe havens, recent underperformance against the broader market has spotlighted companies with weakening fundamentals. We examine three household names where valuation and growth concerns suggest caution is warranted.
While investors chase AI's headline names, optical networking leader Ciena has quietly outperformed the sector. With surging demand for high-speed data transmission and an attractive valuation, it presents a compelling case for the coming year.
Saks Global is closing the majority of its Saks OFF 5TH discount locations, including the final two in Massachusetts, amid a corporate restructuring following its recent bankruptcy filing.
Credit Acceptance (CACC) posted strong fourth-quarter results, surpassing revenue and profit forecasts. The auto finance firm credits its performance to new digital tools for dealers and strategic investments in AI, aiming to deepen partnerships in a competitive market.
Generating cash is just the first step. We analyze three companies to see which ones effectively convert that cash into lasting shareholder value and which ones struggle to capitalize on their financial strength.
Medical device maker ResMed (RMD) reported fourth-quarter revenue of $1.42 billion, an 11% year-over-year increase that surpassed Wall Street forecasts. Non-GAAP earnings per share reached $2.81, also topping analyst expectations.
While low-volatility stocks offer a sense of security, they are not a guaranteed path to growth. We analyze one company with a stable profile and promising outlook, alongside two others where caution may be warranted despite their calm trading history.
Senator Lindsey Graham has stalled a bipartisan funding deal to avert a shutdown, demanding the restoration of a controversial provision allowing lawmakers to sue the Justice Department for damages—a move critics decry as a self-serving scheme.
Swedish investment giant EQT is expanding its footprint through a strategic partnership in the private equity secondaries market with Coller Capital, while its foundation launches a science grant program targeting substitutes for critical minerals. The dual moves signal a broader strategy to tap into new fee streams and align with long-term sustainability trends, even as the firm's shares trade at levels some analysts consider undervalued.
The fast-casual salad chain's stock fell sharply this week, pressured by a broader retreat in growth stocks and a reiterated sell call from Goldman Sachs, despite positive signals from the broader restaurant sector.
Reed Jobs, son of the late Apple co-founder Steve Jobs, has secured over $200 million for Yosemite, a venture fund dedicated to pioneering cancer treatments. Backed by major institutions, the fund seeks to transform cancer from a fatal diagnosis to a chronic, manageable disease within a generation.
Standex International Corporation (NYSE: SXI) capped off its fiscal 2025 with a powerful fourth quarter, announcing record adjusted operating margins of 20.6% and laying out an ambitious roadmap for over $100 million in revenue growth for the coming year. CEO David Dunbar declared a "turning point" for the diversified industrial manufacturer, citing scaled growth drivers in electronics, engineering technologies, and fast-growing markets like grid modernization and defense.
Standex International reports consecutive quarters of record profitability, driven by strategic acquisitions and growth in electrical grid and aerospace markets, while navigating global trade uncertainties.
While the S&P 500 has climbed, Walker & Dunlop shares have tumbled over 14% in six months. We analyze the underlying weaknesses in its financials and highlight a more compelling opportunity for value-focused portfolios.
